1. Home
  2. CBZ vs IMNM Comparison

CBZ vs IMNM Comparison

Compare CBZ & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBIZ Inc.

CBZ

CBIZ Inc.

HOLD

Current Price

$54.50

Market Cap

2.3B

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$24.85

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBZ
IMNM
Founded
1987
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.5B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
CBZ
IMNM
Price
$54.50
$24.85
Analyst Decision
Hold
Strong Buy
Analyst Count
3
10
Target Price
$41.33
$32.80
AVG Volume (30 Days)
1.8M
1.0M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
134.62
51.40
EPS
2.83
N/A
Revenue
$922,003,000.00
$6,941,000.00
Revenue This Year
$3.92
N/A
Revenue Next Year
$4.12
$1,127.34
P/E Ratio
$19.25
N/A
Revenue Growth
7.79
N/A
52 Week Low
$24.29
$8.67
52 Week High
$67.24
$27.65

Technical Indicators

Market Signals
Indicator
CBZ
IMNM
Relative Strength Index (RSI) 81.19 72.37
Support Level $50.29 $19.28
Resistance Level $55.39 $27.14
Average True Range (ATR) 1.02 1.06
MACD 0.80 0.25
Stochastic Oscillator 93.34 87.53

Price Performance

Historical Comparison
CBZ
IMNM

About CBZ CBIZ Inc.

CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the maximum of its revenues from the Financial Services segment and geographically from the United States.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: